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Examining the behavioral consequences of selective
CNS neuronal activation is a powerful tool for eluci-
dating mammalian brain function in health and
disease. Newly developed genetic, pharmacological,
and optical tools allow activation of neurons with
exquisite spatiotemporal resolution; however, the
inaccessibility to light of widely distributed neuronal
populations and the invasiveness required for activa-
tion by light or infused ligands limit the utility of these
methods. To overcome these barriers, we created
transgenic mice expressing an evolved G protein-
coupled receptor (hM3Dq) selectively activated by
the pharmacologically inert, orally bioavailable
drug clozapine-N-oxide (CNO). Here, we expressed
hM3Dq in forebrain principal neurons. Local field
potential and single-neuron recordings revealed
that peripheral administration of CNO activated
hippocampal neurons selectively in hM3Dq-express-
ingmice. Behavioral correlates of neuronal activation
included increased locomotion, stereotypy, and
limbic seizures. These results demonstrate a power-
ful chemical-genetic tool for remotely controlling the
activity of discrete populations of neurons in vivo.
INTRODUCTION
Methods to examine the behavioral consequences of activation
of neuronal ensembles are powerful tools for understandingbrain function, as exemplified by Wilder Penfield’s pioneering
studies of focal electrical stimulation of human cortex (Penfield
and Jasper, 1954). The development of genetic and optical tools
to visualize and activate neuronal activity with exquisite temporal
resolution using microbial opsins (e.g., channelrhodopsin-2, hal-
orhodopsin, Volvox carteri channelrhodopsin, optoXRs) has
provided an expanding toolbox for decoding the neuronal corre-
lates of brain function (Berndt et al., 2009; Boyden et al., 2005;
Li et al., 2005; Zhang et al., 2007, 2008; Airan et al., 2009).
However, the equipment, technological expertise, and invasive-
ness required for light-mediated activation, together with the
relative inaccessibility to light of scattered neuronal populations,
limits the potential applicability of these methods. Ideally, nonin-
vasive remote control of neuronal activity in themammalian brain
would provide a valuable tool for elucidating how the activity of
discrete populations of neurons and local circuits underlies
behavior in health and disease.
Accordingly, we sought to develop a chemical-genetic ap-
proach to control neuronal activity noninvasively in the mamma-
lian brain by regulating signaling through a G protein-coupled
receptor (GPCR). Others have worked toward similar goals (see
Luo et al., 2008, for review), and our work represents an effort
to advance this field. In addition to the opsin-receptor chimeras
(optoXRs)mentionedabove, existing approaches tomanipulating
GPCR signaling pathways in neurons both in vitro and in vivo
include ectopic expression of either GPCRs with engineered
binding sites (e.g., Receptors Activated Solely by Synthetic
Ligands, or RASSLs [Redfern et al., 1999; Zhao et al., 2003]) or
nonnative GPCRs (e.g., the Drosophila allatostatin receptor
[AlstR; Lechner et al., 2002; Tan et al., 2006]). These approaches
represent important advances for the pharmacological manipula-
tion of neuronal activity and are valuable for many applications.Neuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc. 27
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lation of activity of discrete populations of CNS neurons selec-
tively and noninvasively in vivo. RASSLs, for example, are
activated by nonselective, pharmacologically active small mole-
cules and in some tissues exhibit high levels of signaling in the
absence of exogenous small-molecule agonists. Indeed, ectopic
expression of RASSLs can result in pathologic phenotypes (Hsiao
et al., 2008; Peng et al., 2008; Redfern et al., 2000; Sweger et al.,
2007). The AlstR, while displaying no evidence of basal signaling,
does not allow for remotemanipulations of neuronal activity, as its
ligand is unlikely to cross the blood-brain barrier and must be
directly infused into brain tissue (Tan et al., 2006). Moreover, the
AlstR is not used for neuronal activation, as its activity couples
only to neuronal silencing.
To advance thesemethods, we sought to develop a system for
neuronal regulation in which (1) the exogenous ligand would be
pharmacologically inert, (2) the exogenous ligand could be
administered in the periphery and cross the blood-brain barrier
to access receptors in deep brain structures and/or widely
distributed neuronal populations, (3) receptor expression alone
would not induce pathology (4) neuronal activity could be both
increased and decreased, and (5) both spatial and temporal
resolution would be sufficient to facilitate study of brain function
in health and disease.
With this ideal in mind, we used directed molecular evolution to
developanewgenerationofRASSLs,whichwerefer toasDesigner
Receptors Exclusively Activated by Designer Drug (DREADDs),
derived from the human muscarinic receptors (Armbruster et al.,
2007;Conklin et al., 2008;Pei et al., 2008). Thismolecular evolution
resulted in reduced potency and efficacy of the native ligand
(acetylcholine) and high potency and efficacy of the orally bioavail-
able (Bender et al., 1994), pharmacologically inert ligand, cloza-
pine-N-oxide (CNO) (Armbruster et al., 2007; Nawaratne et al.,
2008). Importantly, these DREADDs lack detectable constitutive
activity in vitro (Armbruster etal., 2007) and, thus, provideanattrac-
tive receptor-effector complex for modifying neuronal activity
remotely. Furthermore, this system allows for manipulation of Gi-,
Gq-, and Gs-coupled pathways (Pei et al., 2008).
Here, as a proof of concept, we describe a method by which
the activity of identified populations of CNS neurons is regulated
noninvasively in vivo. For these studies, we produced mice that
express the Gq-coupled human M3 muscarinic DREADD
(hM3Dq) specifically in principal neurons within the forebrain,
particularly in the hippocampus and cortex, by driving expression
in double-transgenic mice in a reversible fashion with the CAM-
KIIa tet transactivator (tTA; Mayford et al., 1996). We then re-
corded local field potential (LFP) and single-unit activity within
hippocampus and showed a correlation between changes in
neuronal activity and behaviors induced by the peripheral admin-
istration of CNO inmutant mice.We demonstrate CNO-mediated
neuronal activation within hippocampus, as measured by dose-
dependent changes in the LFP and increases in the firing rate
of interneurons (likely driven by principal neuron firing). Moreover,
excessive activation of this pathway by high-dose CNO resulted
in limbic seizures and status epilepticus. The selective activation
of GPCRs in defined neuronal populations afforded by this chem-
ical-genetic approach provides an improved tool for the study of
mammalian brain function in health and disease.28 Neuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc.RESULTS
Generation of hM3Dq-Expressing Mice
Previously, we showed in vitro that hM3Dq signals exclusively via
the canonical Gq pathway in nonneuronal cell types (Armbruster
et al., 2007; Conklin et al., 2008). To assess whether hM3Dq
couples to Gq in mixed neuronal-glial cultures, we visualized cal-
ciumfluxwithacalcium-sensitivedye inprimaryculturesofmouse
postnatal day 1 (P1) hippocampal cells infected with hM3Dq-
transducing lentivirus. CNO stimulated calcium transients only
in those neurons expressing hM3Dq (identified by an IRES-driven
mCherry reporter) and was without effect in uninfected neurons
(Figure S1 and Movies S1 and S2 available online).
Having thus demonstrated that hM3Dq conferred the ability to
stimulate neuronal Gq signaling in vitro, we sought to determine
whether expression of hM3Dq could alter neuronal function
in vivo. We first generated transgenic mice expressing tetracy-
cline-sensitive HA-tagged hM3Dq using the Tet-off system (i.e.,
transgeneexpression is represseduponadministrationof tetracy-
cline or its analog, doxycycline). This system allows for inducible,
spatiotemporally regulated transgene expression. Pronuclear
injection of B6SJL hybrid mouse oocytes with Tet Response
Element (TRE)-hM3Dq DNA (Figure 1A) resulted in the birth of
35mouse pups, of which ten carried the transgene. To determine
whetherwe could achieve brain-region-specific expression of the
hM3Dqprotein, we crossed TRE-hM3Dq founderswithCaMKIIa-
tTA mice in which tTA expression is targeted to principal neurons
mainly in cortex,hippocampus,andstriatum (Mayfordet al., 1996)
(Figure 1A). We removed the brains from F1 adults and immuno-
precipitated HA-hM3Dq protein from membrane fractions of
whole-brain (minus cerebellum) homogenates. Initial immunoblot
analysis of the immunoprecipitates revealed expression of
HA-hM3Dq in double-transgenic (both TRE-hM3Dq and tTA
transgenes) F1 progeny from two of the founder mice (data not
shown). Subsequent studies of mutant F1 progeny from both
sets of founder mice did not reveal any differences in receptor
expressionor activity; therefore,we chose only one of the founder
lines (line1) for subsequent studies.Hereafter,we refer to themice
from this line, which express HA-hM3Dq driven by the CaMKIIa
promoter, as hM3Dq mice.
Having determined that the CaMKIIa-tTA transgene effectively
drives hM3Dq expression in the brain, we next sought to repress
hM3Dq expression by doxycycline administration. Immunopre-
cipitation and immunoblot analyses similar to those des-
cribed above revealed undetectable hM3Dq expression in both
hM3DqF1progeny feddoxycycline-containingchow (200mg/kg)
for 1 month and single-transgenic (TRE-hM3Dq transgene only)
mice fed normal chow (Figure 1C). These findings demonstrated,
first, that doxycycline successfully repressed tTA-driven hM3Dq
expression in vivo and, second, that hM3Dq expression could be
temporally regulated.
Characterization of hM3Dq Expression
To examine the spatial distribution of transgene expression, we
prepared coronal brain sections for immunofluorescence and
probed them with an anti-HA antibody. We found that immuno-
fluorescence was most intense in the cortex and hippocampus
(Figures 2A–2C), as expected for CaMKIIa-tTA-driven transgene
Neuron
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immunofluorescence was most intense in CA1 strata radiatum
and oriens (Figure 2A), a pattern consistent with expression in
the apical and basal dendrites of CA1 pyramids. Confocal immu-
nofluorescentmicroscopic analysis of single CA1 pyramidal cells
confirmed immunoreactivity in the soma and apical and basal
dendrites (Figure 2B). Apical dendrite immunoreactivity was
also detected in cortex (Figure 2C). Importantly, inclusion of
doxycycline in the diet resulted in no detectable immunoreac-
tivity in either cerebral cortex or CA1 (compare Figures 2D and
2E). Additionally, a Nissl stain revealed no overt structural differ-
ences betweenWT and hM3Dqmice (Figure S2). To obtain inde-
pendent evidence of hM3Dq expression in the hM3Dq mice, we
measured the Bmax of [
3H] quinuclidinyl benzilate (QNB) binding
in cortical and hippocampal membranes from wild-type and
hM3Dq mice. Radioligand competition binding isotherms were
first modeled based on prior affinity estimates obtained with
cloned wild-type and hM3Dq receptors expressed in vitro
Figure 1. Generation of Transgenic Mice with Inducible Expression
of HA-hM3Dq
(A) Pronuclear injection of mouse oocytes with the 2.36 kb XhoI restriction
digest fragment containing HA-hM3Dq downstream of the Ptight TRE pro-
moter produced a tet-responsive mouse line. When crossed with a CaM-
KIIa-tTA tet-driver line, tTA protein, produced when the CaMKIIa promoter is
active, binds the TRE promoter to activate transcription of HA-hM3Dq; tTA
binding to TRE is inhibited by doxycycline.
(B) Ethidium bromide-stained agarose gel of DNA amplified from tail clips of
a single-transgenic (TRE-hM3Dq) mouse (lane 1), water (lane 2), and
a double-transgenic mouse (lane 3) reveals presence of CaMKIIa-tTA trans-
gene (450 bp), TRE-hM3Dq transgene (250 bp), and mouse genomic DNA
control band (200 bp).
(C) Immunoprecipitation followed by immunoblot does not detect any trans-
gene in single-transgenic mice (TRE-hM3Dq transgene only, lane 1) or
double-transgenic (hM3Dq) mice maintained on 200 mg/kg doxycycline
(lane 3), in contrast to hM3Dq mice maintained on normal chow in which HA
protein is detectable (lane 2). b-actin was detected as a loading control. Mouse
brains (with cerebellum removed) were homogenized, and the membrane-
containing fraction was isolated through differential centrifugation. HA-affinity
matrix immunoprecipitated HA-tagged proteins, which were then separated
by SDS-PAGE and detected by western blot with anti-HA antibody.(KD = 0.05 nM at hM3; KD = 1.6 nM at HA-hM3Dq; Armbruster
et al., 2007).We conducted computerized simulations with Prism
4.0 using different concentrations of [3H]QNB and various ratios
of native to transgenic receptor expression in order to determine
the optimal concentration of [3H]QNB, a nonselective muscarinic
antagonist, for detection of both endogenous muscarinic recep-
tors and hM3Dq receptors. Having determined the optimal assay
conditions, competition curves were then obtained using unla-
beled acetylcholine (which binds hM3Dq, albeit with lower
affinity compared to wild-type mAChRs; Armbruster et al.,
2007) and [3H]QNB. Data were fit simultaneously by LIGAND
(Munson and Rodbard, 1980) using weighted nonlinear regres-
sion analysis and a two-site model, which best described all
data sets (by F test). In hM3Dq tissue, a distinct site emerged
for which ACh had low affinity (1.0 mM in cortex, 1.7 mM in
hippocampus) (Figure 2F and Table S1). The affinity of ACh for
this site was similar to that of ACh for cloned hM3Dq, but not
wild-type muscarinic, receptors (Armbruster et al., 2007). The
inclusion of doxycycline in the diet of hM3Dq mice eliminated
this low-affinity site (Table S1). We concluded that (1) this low-
affinity ACh site accounted for the difference in Bmax between
hM3Dq and wild-type or doxycycline-treated tissue and that (2)
the difference in Bmax was due to hM3Dq transgene expression.
Indeed, computerized nonlinear least-squares regression
analysis taking into account the difference in affinity of [3H]QNB
for the hM3Dq and native mAChRs revealed an increase of
4- and 7-fold in the Bmax of [
3H]QNB binding to membranes iso-
lated from cortex and hippocampus, respectively, of hM3Dq
compared toWTmice (Figure 2G and Table S1). These data indi-
cate that hM3Dqwasexpressed inboth cortex andhippocampus
at levels greater than endogenous muscarinic receptors.
Behavioral Analyses of hM3Dq Mice in the Absence
of CNO
Amajor goal of the evolution of the second generation of RASSLs
was to minimize constitutive activity of hM3Dq and also to elim-
inate the activation of hM3Dq by endogenous ACh, thus limiting
hM3Dq signaling in vivo in the absence of CNO.When expressed
in yeast, cultured mammalian cells, and mouse pancreatic
b-cells, no detectable constitutive activity of hM3Dq in the
absence of CNOwas found (Armbruster et al., 2007; J.-M. Guet-
tier et al., personal communication). To test whether hM3Dq
expression in vivo modified behavior in the absence of its exog-
enous activating ligand (CNO), we examined mouse appearance
and behavior through a battery of neurobehavioral tests on
single-transgenic (TRE-hM3Dq transgene only) and hM3Dq
mice (see Supplemental Experimental Procedures and Figures
S3–S7; n = 11 littermate pairs). No qualitative differences were
evident between control and hM3Dq mice. Specifically, the two
groups were similar in observations regarding size, overall
morphology, coat condition, body posture and gait, reflex
response to gentle touch with a cotton swab on the whiskers or
eyes, balance in an empty, shifting plastic cage, ability to climb
a pole or walk across an elevated dowel, grip-strength in a
wire-hang test, and responses during 20 s of tail-suspension.
A variety of quantitative assessments of behavior were also
performed. We quantified motor coordination using an acceler-
ating rotarod, the results of which revealed no significantNeuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc. 29
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wise, no significant differences were detected in the elevated
plus maze, acoustic startle response, prepulse inhibition of
startle responses (PPI), latency to locate a food reward buried
in bedding, the Morris water maze visual cue test, or acquisition
and reversal learning in the Morris water maze (Figures S4–S6).
In contrast to these measures that revealed no differences
between the two genotypes, we did find subtle but unremarkable
differences with respect to activity in an open field (Figure S7).
hM3Dq mice demonstrated a tendency toward reduced loco-
motor activity as measured by total distance traveled in a loco-
motor chamber [F(1,20) = 6.15, p < 0.05] (Figure S7A). They
further demonstrated fewer fine, stereotypic movements
[F(1,20) = 6.63, p = 0.0181] (Figure S7B). However, no differences
in rearing movements or in time spent in the center of the open
field were detected (data not shown). Apart from the mild reduc-
tion of spontaneous locomotor activity, the hM3Dq mice were
similar to controls on an extensive battery of tests of diverse
behaviors, implying that overexpression of a Gq-coupled
receptor has minimal untoward effects.
In Vitro CA1 Pyramidal Cell Response to CNO
After characterizing the behavior of hM3Dq mice in the absence
of exogenous ligand, we sought to determine the effects of
Figure 2. Receptor Expression and Localization in
Transgenic Mouse Brains
(A–E) Immunohistochemistry for HA-tagged protein in coronal
sections from hM3Dq mouse brain; HA immunoreactivity
localizes to the CA1 region of the hippocampus (A) where
staining is specifically observed in the apical and basal
processes of pyramidal neurons (B). In the cortex (C), immuno-
reactivity is detected in apical dendrites. HA immunoreactivity
is present in mutant mice fed normal chow (D) but not in mice
maintained on 200 mg/kg doxycycline (E).
(F) [3H]QNB binding to cortical (left panel) and hippocampal
(right panel) mouse brain membranes was determined by
radioligand competition-binding assays. Competition curves
depict data (mean ± SEM) from one representative animal
of each group. Data were fit simultaneously by nonlinear
regression.
(G) Mice expressing hM3Dq protein have a higher Bmax of
[3H]QNB binding than wild-typemice or hM3Dqmice on doxy-
cycline. Data represent mean ± SE. *p < 0.05 by F test.
hM3Dq receptor activation by CNO. We first asked
whether neurons from hM3Dq animals would
respond to CNO. To address this question, we iso-
lated acute hippocampal slices from hM3Dq and
littermate control animals and performed whole-
cell recordings from CA1 pyramidal neurons in the
absence and presence of bath-applied CNO. To
isolate membrane potential responses from
synaptic responses, we performed these record-
ings in the presence of tetrodotoxin (TTX). We
found that bath application of CNO (500 nM) to
hippocampal slices isolated from hM3Dq mice
depolarized CA1 pyramidal cells by 8.0 ± 1.8 mV
compared with baseline membrane potentials
(p < 0.01; n = 7 neurons from 5 animals; Figures 3Ai and 3Aiii).
In contrast to these findings in hM3Dq mice, we found no signif-
icant change inmembrane potential of CA1 pyramidal neurons of
hippocampal slices isolated from control (either single trans-
genic or wild-type) mice (p > 0.05, n = 7 neurons from 5 animals;
Figures 3Aii an 3Aiii). We additionally asked whether bath appli-
cation of CNO to hippocampal slices isolated from hM3Dq mice
would increase the firing rate of CA1 pyramidal neurons. To that
end, we performed whole-cell recordings from CA1 pyramidal
cells in the absence of TTX. We found that bath application of
CNO (500 nM) in the absence of TTX increased the firing rate
of CA1 pyramidal cells (n = 8 neurons from 4 animals; Figure 3C).
Because Gq signaling can affect membrane conductances
through phospholipase C (PLC)-dependent mechanisms, we
tested the dependence of the CNO-evoked depolarization on
PLC. We performed whole-cell recordings from CA1 pyramidal
cells in acute slices isolated from hM3Dq animals in the presence
of TTX and the PLC inhibitor, U73122 (10 mM), and then bath
applied CNO (500 nM). We found that in the presence of
U73122, CNO had no significant effect on the membrane poten-
tial of CA1 pyramidal cells (p > 0.05, n = 6 neurons from
4 animals; Figures 3Bi and 3Biii). By contrast, in the presence
of U73343 (10 mM), the inactive analog of U73122, CNO
produced a significant depolarization of CA1 pyramidal neurons30 Neuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc.
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3Bii and 3Biii). These findings indicate that CNO-induced activa-
tion of hM3Dq depolarizes and increases the firing rate of CA1
pyramidal neurons through a PLC-dependent mechanism.
Behavioral Response of hM3Dq Mice to CNO
Treatment of hM3Dq but not WTmice with CNO induced striking
behavioral effects. Using a cohort of adult mice distinct from that
in which baseline behavioral characterization was performed, we
measured ambulation and episodes of repetitive beam breaks
(generally representing fine movements or stereotypic behav-
iors) following peripheral administration of vehicle (saline) and
low-dose (0.1 and 0.3 mg/kg) CNO (n = 10 hM3Dq; n = 14
controls). Among hM3Dq mice, significant behavioral effects
were noted. When CNO was administered, activity (both total
ambulation and repetitive beam breaks) increased in a dose-
dependent fashion among hM3Dq mice and exceeded control
Figure 3. CNO Effects on CA1 Pyramidal Neurons Recorded In Vitro
Acute hippocampal slices were isolated from hM3Dq and control animals, and
CA1 pyramidal cells were recorded from in the whole-cell configuration. Cells
were held at resting membrane potential in the presence (A and B) or absence
(C) of TTX, and CNO was bath applied.
(A) Bath application of CNO (500 nM) depolarized CA1 pyramidal cells from
hM3Dq animals (Ai), but CNO (1 mM) did not affect resting membrane potential
of CA1 pyramidal cells from control animals. However, bath application of
carbachol (5 mM) did depolarize CA1 pyramidal cells from control animals
(Aii). (Aiii) Population data from hM3Dq and control animals showing the
mean (±SEM) resting membrane potential of CA1 pyramidal cells before and
in the presence of CNO (500 nM for hM3Dq [n = 7 cells from 5 animals] and
1 mM for control animals [n = 7 cells from 5 animals]).
(B) In the presence of an active PLC inhibitor (U73122, 10 mM), the CNO-
induced depolarization of hM3Dq CA1 pyramidal neurons was blocked (Bi),
but in the presence of an inactive analog (U73343, 10 mM), CNO was capable
of depolarizing hM3Dq CA1 pyramidal neurons (Bii). (Biii) Population data
showing the mean (±SEM) resting membrane potential of hM3Dq CA1 pyra-
midal neurons before and after application of CNO (500 nM) in the presence
of U73122 (n = 6 cells from 4 animals) or U73343 (n = 4 cells from 4 animals).
(C) Bath application of CNO (500 nM) to hippocampal slices isolated from
hM3Dq animals in the absence of TTX resulted in increased firing frequency
and recurrent bursting.levels. The administration of 0.1 mg/kg CNO resulted in a signif-
icant increase in repetitive beam breaks (p < 0.01) and a trend
toward a significant increase in total locomotion in hM3Dq
mice relative to controls. Administration of 0.3 mg/kg CNO
produced a statistically significant increase in both total locomo-
tion and repeated beam breaks in hM3Dq mice relative to
controls (p < 0.01; Figures 4Ai and 4Bi). Furthermore, the
increases in locomotion and repetitive beam breaks following
CNO administration occurred in a time-dependent manner,
such that locomotor activity gradually increased with time rela-
tive to controls (Figures 4Aii and 4Bii), and the increase in loco-
motor activity persisted >9 hr (Figure 7A; n = 4 hM3Dq; n = 4
controls). These data provide behavioral evidence of neuronal
activation by CNO in hM3Dq mice and demonstrate the long
duration of CNO activity in hM3Dq animals. To assess the behav-
ioral responses of hM3Dq mice to higher doses of CNO, we
observed control and hM3Dq mice treated in parallel with saline
or increasing doses of CNO. We found that treatment of hM3Dq
mice with 0.5 mg/kg CNO reliably evoked limbic seizures of
behavioral class 1 (Figure 4Ci); no behavioral evidence of seizure
activity was detected after administration of lower doses (0.03,
0.1, or 0.3 mg/kg CNO). Treatment with doses of CNO higher
than 0.5 mg/kg evoked continuous seizure activity of classes 3
through 7, namely status epilepticus (SE) and death. CNO at
doses of 1 or 5 mg/kg evoked SE in two of four animals and
five of seven animals (Figure 4Cii). Among the five animals in
which SE was elicited by 5 mg/kg CNO, an orderly progression
of behavioral seizure intensity was observed over time following
CNO treatment (Figure 4Ciii). The latency to onset of the first
class 1 seizure was 15.4 ± 3.7 min. SE was lethal in four of the
seven animals during the 3 hr following SE onset. Whereas
CNO reliably evoked seizures in hM3Dq animals, CNO evoked
no behavioral seizures in control animals at any dose tested
(0.03–5 mg/kg; n = 4 carrying the tTA transgene alone; n = 2
carrying the TRE-hM3Dq transgene alone; n = 5 wild-type
animals).
In Vivo Recordings from Hippocampus
Wenext sought to examine the electrophysiological correlates of
the behavioral effects of CNO in the hM3Dq mice. Because the
behavioral features of the seizures were typical for seizures
arising from hippocampus and because hM3Dq is expressed
in hippocampal neurons, we focused on the hippocampus.
Toward this end, we implanted control and hM3Dq mice with
multielectrode arrays to monitor both LFPs and spike activity
of multiple individual neurons in the hippocampus. These
in vivo recordings were performed during the same sessions
as the behavioral seizure observations described above. CNO
increased neuronal activity in a dose- and time-dependent
fashion as measured by both LFP and single-unit firing rate
(Figures 5 and 6). With respect to the dose-dependent change
in neuronal activity, we found that treatment of hM3Dq mice
with saline (Figure 6C) or 0.03 mg/kg CNO (Figure 5Ai) produced
no significant change in the LFP or in single-unit firing, consistent
with the lack of behavioral effects of these doses. However,
doses of 0.1 mg/kg to 1 mg/kg elicited successively greater
increases in power of the gamma frequency band of the LFP
(Figure 5B). At the subconvulsive doses of 0.1 mg/kg andNeuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc. 31
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seen in the LFP, with 0.3 mg/kg eliciting a greater magnitude of
gamma power increase (Figures 5Aii, 5Aiii, and 5B). In addition,
Figure 4. Behavioral Consequences of CNO Administration
(A and B) Effect of CNO administration on locomotor behavior in control and
hM3Dq mice (n = 10 hM3Dq and 14 control mice). CNO increased total loco-
motor activity shown as mean (±SEM) distance traveled (A) and mean (±SEM)
number of repetitive beambreaks (B) in a dose-dependent (Ai andBi) and time-
dependent (Aii and Bii) manner in hM3Dq mice relative to control animals. For
(Aii) and (Bii), CNO was administered at time 0 following a 20 min habituation
period in the locomotor chamber.
(C) Behavioral seizure classes evoked by CNO administration (n = 7 hM3Dq
animals). All data presented here were measured during the 3 hr following
CNO administration when SE did not occur and during the 3 hr following SE
onset when SE did occur. (Ci) Mean (±SEM) maximum behavioral seizure class
elicited by various doses of CNO. No seizures were elicited by doses less than
0.5 mg/kg CNO. (Cii) Percent of animals in which SE occurred at various doses
of CNO. SE did not result from doses less than 1 mg/kg. (Ciii) Mean (±SEM)
latency fromCNO administration to first occurrence of each behavioral seizure
class for animals administered 5 mg/kg CNO. *p < 0.05, **p < 0.01.32 Neuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc.during the period of increased gamma power, we found an
increase in the firing rate of hippocampal interneurons (Figures
5 and 6). Treatment of hM3Dq mice with convulsant doses of
CNO (0.5, 1, and 5mg/kg) induced striking alterations in neuronal
activity evident in both LFP and single-unit activity (Figures 5Aiv–
5vi). Notably, spectral analyses of LFP activity revealed an
increase in gamma power preceding the onset of seizures
(Figures 5Avi and 6D). Analyses of single-neuron firing frequency
revealed an increase in interneuron firing frequency that coin-
cided with the increased gamma power in the LFP. This pattern
of single-neuron firing persisted until the onset of seizures, at
which point interneuron firing dramatically decreased (Figures
5 and 6). By contrast, treatment of hM3Dq mice with saline
induced no significant change in LFPs or the firing frequency of
interneurons (Figure 6C). Likewise, treatment of control mice
with either CNO or saline induced no significant change in LFP
spectral parameters or firing rate of interneurons (Figures 6A
and 6B).
We also assessed the time-dependent changes in neuronal
activity following CNO administration. The effect of CNO on the
LFP, as measured by changes in gamma power, was first seen
between 5 and 10 min after CNO administration and peaked
between 45 and 50min for all doses tested (Figure 5C). To deter-
mine the duration of CNO effects on neuronal activity, we admin-
istered CNO (0.3 mg/kg or 0.5mg/kg) and recorded LFP for 24 hr
(n = 3 mice for 0.3 mg/kg; n = 2 mice for 0.5 mg/kg). At both
doses tested, the CNO-induced increase in gamma power per-
sisted for 9 hr (Figure 7B), paralleling the pattern we observed
in locomotor activity (Figure 7A). These data suggest that the
offset kinetics are not dependent on CNO dose. Moreover,
24 hr after the first 0.3 mg/kg dose, we readministered CNO
(0.3 mg/kg) to the same mice and found no significant difference
in peak gamma power response or duration of this response
between day 1 and day 2, indicating that sensitivity to CNO, at
least with 24 hr between administrations, was unaltered by
such long-lasting effects (Figure 7Bii).
Efficiency of Tet-Off System in hM3Dq Mice
As described above, doxycycline virtually eliminated hM3Dq
protein expression as assessed by radioligand binding assays,
western blot analysis, and immunofluorescence microscopy.
To assess whether doxycycline also eliminates the behavioral
and electrophysiological responses to CNO, hM3Dq mice were
treated with doxycycline for 4 weeks and behavioral and electro-
physiological responses to CNO were assessed. CNO (0.3 and
5 mg/kg) induced no locomotor response with respect to either
total distance traveled (Figure 8Ai) or repetitive beam breaks
(Figure 8Aii) in hM3Dq mice treated with doxycycline (n =
5 mice). Moreover, behavioral seizures and alterations in LFP,
as measured by spectral analysis, were notably absent from
hM3Dq mice administered CNO (5 mg/kg) during doxycycline
treatment (Figure 8Bi; n = 3 mice). To assess the reversibility of
doxycycline suppression of transgene expression on the electro-
physiological response, administration of doxycycline was
terminated, and 4 weeks later the same mice were treated again
with CNO (5 mg/kg) (Figure 8Bii). In this case, CNO induced
increased power in the gamma frequency band as detected by
LFP recordings as well as behavioral seizures culminating in
Neuron
In Vivo Neuronal Modulation via DREADDsSE and death, thereby demonstrating both the reversibility of
doxycycline suppression of transgene expression and the spec-
ificity of CNO’s effects for the hM3Dq receptor.
DISCUSSION
Here, we report a chemical-genetic approach for the experi-
mental manipulation of CNS neuronal activity. We paired a tetra-
cycline-repressible tissue-specific genetic system, which
provided transgenic mice with inducible, reversible, and spatially
controlled transgene expression, with a specific and selective
pharmacologic system (e.g., second-generation DREADD-type
RASSLs) to achieve remote spatial control over neuronal activity
in vivo. In coupling these two systems, we demonstrated
controlled activation of Gq-coupled pathways, resulting in
striking behavioral and electrophysiological changes. Many
systems are now available for controlling neuronal activity,
each with its particular advantages and disadvantages. The
technique we describe here provides an additional tool with
some important advantages over existing approaches.
Utility of the DREADD System for In Vivo Applications
Several features of second-generation RASSLs tailor them for
in vivo use, as exemplified by the hM3Dq mouse in this study.
First, neuronal activation in hM3Dq animals is highly selective;
CNO has no detectable off-target actions. Using multiple read-
outs including animal activity, in vitro slice recordings, and
in vivo multielectrode array recordings, we detected no effect
of CNO in wild-type, single-transgenic, or doxycycline-treated
double-transgenic animals. In this respect, our approach is an
improvement upon its RASSL predecessors, as the small-mole-
cule agonists of first-generation RASSLs are pharmacologically
active and necessitate a knockout background (Scearce-Levie
et al., 2001). Together with a tissue- or even cell-specific genetic
or viral system, these second-generation RASSLs thus allow one
to target specific cell types or networkswithout interference from
undesired ligand actions.
Second, our approach enables noninvasive modulation of
neuronal activity. CNO, like other RASSL ligands, can be injected
peripherally (or provided through drinking water; unpublished
data) and crosses the blood-brain barrier to activate receptors
in discrete and even widely distributed cell populations. In
contrast, other systems for neuronal manipulation (e.g., micro-
bial opsins and optoXRs, AlstR, the ligand-gated ion channel
TRPV1 [Arenkiel et al., 2008]) require direct application of light/
ligand to brain tissue in order to alter neuronal activity and thus
have spatial limitations with regard to cells that can be activated
at a given time. Although the invasive procedures mandated by
those systems are not a hindrance for all applications, remote
control of neuronal activity could be beneficial in some
instances, in particular for readouts such as animal behavioral
tasks, which are exquisitely sensitive to handling stress, or for
the activation of diffusely distributed populations of cells. More-
over, because neurons can be activated noninvasively in hM3Dq
animals, this technology is more readily accessible than optical
approaches or the AlstR and TRPV1 systems. Once mice with
the desired pattern of receptor expression have been generated,
the receptor can easily be activated by peripheral injection;stereotaxic apparatus, light sources, fiberoptics, and the tech-
nological expertise they require are thus unnecessary.
Third, hM3Dq activation is dose dependent, allowing one to
titrate the level of receptor activity by varying the dose of CNO.
In the absence of CNO, we were able to detect only a single
difference in hM3Dq mice compared to controls, despite exten-
sive observations and behavioral testing. Whether the mutant
receptor lacks constitutive activity, whether the concentration
of acetylcholine in the synaptic cleft is insufficient to activate
hM3Dq given its reduced potency at the mutant receptor, or
whether the lack of phenotype represents homeostatic neuronal
equilibration is unclear. However in vitro evidence (Armbruster
et al., 2007) together with the fact that mice expressing hM3Dq
in pancreatic b cells exhibit no detectable phenotype in the
absence of CNO (J.-M. Guettier et al., personal communication)
suggests that neuronally expressed hM3Dq exhibits little consti-
tutive activity and is insensitive to endogenous acetylcholine.
In response to CNO administration, we describe both behav-
ioral changes following low doses of CNO (0.1 and 0.3 mg/kg)
and mild to severe seizures and status epilepticus resulting
from higher doses of CNO (0.5, 1.0, 5.0 mg/kg). Moreover,
dose-dependent LFP alterations are present at all doses from
0.1 to 5.0 mg/kg. In this case, the high levels of hM3Dq overex-
pression may increase the dynamic range of the system. In the
absence of CNO, the system is apparently silent. At low doses
of CNO, occupancy of a small proportion of hM3Dq results in
subtle phenotypes; by contrast, occupancy of higher proportions
of hM3Dq with higher doses of CNO yields more profound
effects. This characteristic of the second-generation RASSLs
increases their applicability to experimental manipulations, as it
provides the user considerable control over theextent of receptor
activation. By contrast, when expressed in certain tissues, the
first generation of RASSLs occasionally signals at high levels in
theunstimulated state and results in significant pathologies (Red-
fern et al., 2000; Sweger et al., 2007; Peng et al., 2008; Hsiao
et al., 2008), thereby preventing one from precisely titrating the
level of receptor activity by exogenous ligand application.
Together, these aspects of the approach described here—its
selectivity, noninvasiveness, and dynamic range, as well as the
spatiotemporal control over receptor expression that mouse
genetics affords—render this technique attractive for in vivo
manipulations of neuronal signaling. Additionally, although we
report here only the ability of theGq-coupledDREADD to activate
neuronal firing viaPLC-dependent pathways,Gi- andGs-coupled
DREADDs permit the manipulation of other GPCR signaling
cascades to effect alternative endpoints (S.M. Ferguson and
J.F. Neumaier, personal communication; J.-M. Guettier et al.,
personal communication). Thus, the DREADD system is well-
suited for investigating diverse experimental questions. While
drawbacks persist, this system is nonetheless an improved and
valuable tool for analysis of how the activity of discrete popula-
tions of neurons and local circuits underlies behavior.
Molecular and Cellular Etiology of the hM3Dq
Mouse Phenotype
For this proof-of-concept study of hM3Dq function in vivo, we
employed the CaMKIIa-tTA Tet-Off system to drive expression
of a Gq-coupled GPCR in forebrain principal neurons. In additionNeuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc. 33
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In Vivo Neuronal Modulation via DREADDsFigure 5. CNO Dose-Dependently Increases Neuronal Activity and Gamma Power in hM3Dq Mice
(A) CNO administration to hM3Dq mice evoked dose-dependent increases in hippocampal neuronal activity (Ai–Avi), as seen by increased power in the
gamma frequency band of the LFP and associated increased firing rate of presumed interneurons. Spectrograms show the power of all frequencies up to
100 Hz over the course of the recording session, with warmer colors representing greater power. Plots below spectrograms represent single-unit firing rate
of presumed interneurons, and each row corresponds to a single neuron. Here, warmer colors represent greater firing frequency. Classification of neurons as
interneurons was based on firing frequency and pattern of firing. Arrows indicate the time at which CNO was administered s.c. at the dose indicated on each
spectrogram.34 Neuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc.
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In Vivo Neuronal Modulation via DREADDsto validating our technique for selective neuronal activation, this
system allowed us to investigate Gq signaling cascades—both
the molecular mediators of signal transduction and the pathology
stemming from its overactivation—in thisneuronal subpopulation.
Using the in vitro slice preparation, we demonstrated that CNO
directly depolarizes pyramidal cells from hM3Dq mice and does
so in an apparently PLC-dependent manner; the active PLC
inhibitor U73122, but not its inactive analog U73343, blocked
the depolarizing effect of CNO. The observed PLC dependence
of CNO’s effects on hM3Dq neurons is expected based on
previous characterization of the specificity with which hM3Dq
couples to Gq (Armbruster et al., 2007). The magnitude and
kinetics of the CNO-induced depolarization and its PLC de-
pendence suggests that one mechanism by which CNO may
depolarize neurons is through inhibition of M current, a slowly in-
activating, outwardly rectifying potassium current important for
depression of neuronal excitability (Brown and Yu, 2000). M
current is carried by PIP2-gated KCNQ channels (Wang et al.,
1998; Zhang et al., 2003; Biervert et al., 1998). Importantly, hu-
mans with benign familial neonatal convulsions, an autosomal-
dominant form of neonatal epilepsy, carry an insertion in their
KCNQ2 gene that yields a nonfunctional protein (Biervert et al.,
(B) Peak power in the gamma frequency range measured from the LFP before and after administration of various doses of CNO displayed as mean (±SEM)
percent of baseline gamma power (n = 4 hM3Dq and 11 control animals).
(C) Time course of peak LFP gamma power change from baseline following administration of various doses of CNO. CNOwas given at 0 min, and each data point
represents the mean (±SEM) percent of baseline gamma power. **p < 0.01.
Figure 6. Local Field Potential and Single-Unit Recordings from Hippocampus of Control and hM3Dq Animals Administered Either Saline or
1 mg/kg CNO Subcutaneously
For (A)–(D), i represents local field potential recordings. Spectrograms show the power of all frequencies up to 100 Hz over the course of the recording session,
with warmer colors representing greater power. Letters on each spectrogram correspond to the example LFP epochs shown above each spectrogram. Arrows
represent the time at which either saline or CNO was administered. ii in (A)–(D) shows the firing frequency of individual putative interneurons recorded in hippo-
campus. Here, warmer colors represent greater firing frequency. Classification of neurons as interneurons was based on firing frequency and pattern of firing. As
shown in the inset autocorrelogram between (A) and (C), interneurons tended to fire tonically, as previously described (Henze et al., 2002). In (Di), CNO (5 m/kg)
elicited increased power in the gamma frequency range (b) before the onset of seizures (c). Arrowheads in (D) indicate occurrence of isolated electrographic
seizures, and SE represents onset of uninterrupted electrographic seizure activity.Neuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc. 35
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In Vivo Neuronal Modulation via DREADDsFigure 7. Behavioral and In Vivo Electrophysiological Time Course of CNO Effects in hM3Dq Animals
(A) Time course of CNO effects on locomotor activity, as measured by mean (±SEM) total distance traveled (Ai) and repeated beam breaks (Aii), showing the
latency to recovery of elevated locomotor activity following administration of 0.3mg/kg CNO, which was administered at time 0 (n = 4 littermate pairs). Data points
represent the mean (±SEM) total distance traveled (Ai) or number of repeated beam breaks (Aii) for all animals.
(B) Time course of CNO effects on gamma power measured from the hippocampal LFP showing the latency to recovery of gamma power to baseline levels. (Bi)
Representative spectrogram of LFP from hM3Dq animal administered 0.3 mg/kg CNO at time 1.5 hr. (Bii) Population data demonstrating time course of acutely
administered CNO on gamma power and gamma power response to two injections of CNO administered 24 hr apart from one another. The time course of onset
and offset of CNO effects, as measured by changes in gamma power, was measured during an acute administration of either 0.3 mg/kg (closed black squares;
n = 3 hM3Dq animals) or 0.5 mg/kg (open red circle; n = 2 hM3Dq animals) CNO to determine dose-dependence of onset and offset kinetics. Twenty-four hours
following the acute administration of 0.3 mg/kg CNO (day 1; closed black squares), a second injection of 0.3 mg/kg CNO was administered to the same animals,
and gamma power responsewasmonitored (day 2; open black circles) for the purpose of assessing desensitization of the hM3Dq receptor. Data points represent
the mean (±SEM) percent of baseline gamma power for all animals studied in this experiment.1998). Activation of PLCb by numerous Gq-coupled GPCRs
causes PIP2 hydrolysis, which reduces PIP2 content, closes
KCNQ channels, and inhibits M current, resulting in neuronal
depolarization and a propensity for neurons to fire bursts rather
than tonic spikes (Zhang et al., 2003). While the closing of KCNQ
channels is an appealing hypothesis for the molecular mecha-
nism of hM3Dq action, further in vitro studies employing specific
KCNQ channel blockers will be necessary to demonstrate its
validity.
Given our hypothesis that neuronal depolarization occurs at
least in part through inhibition of M current in hM3Dq-expressing
neurons, it is unknown to what extent hM3Dq signaling might
differ in other cell types or brain regions that do not express
KCNQ channels (e.g., cerebellum; Wang et al., 1998). Examining
the diverse consequences of activating the same molecular
signaling pathway in different cell types is an attractive applica-
tion of the DREADD system and provides just one example of the
many uses for this technology.
Our in vivo electrophysiology studies provide insights into the
mechanism of CNO’s actions at the cellular and systems level in
hM3Dq mice. We found that CNO evoked dose-dependent
increases in gamma power as detected by spectral analyses of
LFP recordings from hippocampus, selectively in hM3Dq mice.
This increased gamma power was associated with an increase
in hippocampal interneuron firing rate. We propose that36 Neuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc.hM3Dq activation modifies local hippocampal circuit activity by
activating principal cells, which synaptically activate interneuron
firing, thereby producing gamma oscillations. This hypothesis is
based on three lines of evidence. First, the pattern of hM3Dq
expression, coupled with the in vitro data described above,
suggests that CNO’s direct effects are restricted to principal
excitatory neurons. hM3Dq expression is driven by the principal
neuron-specific CaMKIIa promoter (Hanson and Schulman,
1992), and HA immunoreactivity, representing hM3Dq expres-
sion, is absent from the parvalbumin-positive interneuron cell
bodies (Figure S8) shown to contribute to the gamma rhythm
(Bartos et al., 2007; Cardin et al., 2009). Second, our findings
of persistently increased gamma power are consistent with
previously described pharmacological models of gamma induc-
tion. For example, bath application of the muscarinic agonist
carbachol to hippocampal slices in vitro is sufficient to induce
gamma frequency field potentials that persist long after the
drug has washed from the bath (Fisahn et al., 1998). Third, the
proposed mechanism by which the gamma rhythm is induced
in the carbachol model of gamma oscillations includes excitation
of pyramidal cells, leading to persistent synchronous firing of a
circuit of interneurons connected by gap junctions. As described
above, our in vitro whole-cell recordings from CA1 pyramidal
cells revealed that CNO directly depolarizes pyramidal cells,
and our in vivo hippocampal recordings revealed that CNO
Neuron
In Vivo Neuronal Modulation via DREADDsFigure 8. Doxycycline Treatment of hM3Dq Animals Prevents CNO-Induced Behavioral and Electrophysiological Changes
(A) CNO administration to hM3Dq animals not exposed to doxycycline produced increased locomotor activity as measured by total distance traveled (Ai) and
repetitive beam breaks (Aii). However, 4 weeks of doxycycline exposure inhibited CNO-induced changes in locomotor activity (n = 5 hM3Dqmice). Bars represent
mean (±SEM) total distance traveled (Ai) or number of repetitive beam breaks (Aii) for all animals in each group.
(Bi) Four weeks of doxycycline exposure inhibited CNO (5mg/kg) induced changes in the LFP. No increase in gamma power was elicited, and no seizures resulted
from CNO administration. (Bii) Following 4 weeks of doxycycline exposure, animals were taken off doxycycline for 4 weeks and challenged with CNO (5 mg/kg)
again. At this time, CNO elicited increased power in the gamma frequency range (b) and subsequent SE (c).produces increased interneuron firing rate. Thus, we conclude
that the increased gamma rhythm and behavioral consequences
of CNO administration to hM3Dq mice are the result of hM3Dq
directly activating excitatory pyramidal neurons that subse-
quently induce synchronous interneuron firing. We further
conclude that the CNO-evoked seizures are triggered by activa-
tion of excitatory pyramidal neurons, but the precise cellular
events mediating the transition from increased gamma rhythm
into seizure activity remain to be elucidated.
Potential Limitations of DREADD Technology
While the second-generation RASSLs (DREADDs) described
here overcome some of the previous problems plaguing experi-
mental manipulation of neuronal signaling, we acknowledge
potential limitations of this system.
The primary disadvantage of the DREADD system in general,
and these hM3Dq mice in particular, is the relatively coarse
temporal resolution of neuronal manipulation. We have thor-
oughly characterized the kinetics of activation of hM3Dq and
the ensuing electrophysiological response and shown activation
to begin between 5 and 10 min after injection, with peak electro-
physiological responses occurring 45–50 min after injection. We
determined that both the behavioral and electrophysiological
effects of CNO in hM3Dq mice are persistent, with responses
not returning to baseline for many hours. Both the onset and
offset kinetics were unrelated to the dose of CNO. While thekinetics of onset of the CNO response are likely similar to that
of other systemically administered drugs, including other RASSL
ligands, they are certainly slower than that of locally infused
ligands such as allatostatin (for AlstR) or capsaicin (for TRPV1),
which occur on the order of minutes, or the microbial opsins,
whose activation occurs on the order of milliseconds. The
latency to onset of CNO’s effects is likely due to the pharmaco-
kinetic properties of CNO. In contrast, the duration of CNO’s
effects could be specific to the neuronal population in which
hMDq is expressed and the signaling events the receptor medi-
ates; hM3Dq expression in other tissues might not elicit such
persistent effects. Thus, while CNO allows for noninvasive
control of activity in select populations of CNS neurons in a freely
moving adult mouse, the temporal resolution of that control is
coarse, particularly in comparison to microbial opsins.
The kinetics of inactivation of hM3Dq signaling in vivo might
prove to be a greater limitation of this technology than those of
activation. As shown by both locomotor and electrophysiological
activity, the response to subseizure doses of CNO is long-
lasting, with responses returning to baseline9 hr after injection.
Clearly, for applications requiring defined termination points,
these hM3Dq mice are not well suited. While the enduring
responses may represent continual hM3Dq activation by CNO,
three facts lead us to favor the idea that they are due to regener-
ative downstream events within hM3Dq-expressing neurons
and/or to activation of other neuronal populations. First,Neuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc. 37
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persists following removal of carbachol from the bath (Fisahn
et al., 1998), demonstrating that fleeting activation of muscarinic
receptors can induce persistent responses. Second, CNO is
removed from plasma within 2 hr of injection, without back-
metabolism to clozapine (J.-M. Guettier et al., personal commu-
nication), arguing against persistent CNO-mediated activation of
hM3Dq. Third, the time course of CNO-evoked physiological
effects in transgenic mice expressing hM3Dq in pancreatic
b cells correlates with the plasma concentration of CNO, with
effects diminishing within 2 hr (J.-M. Guettier et al., personal
communication). It will be important for future users of DREADD
technology to fully characterize the timing of offset of effects in
each cell population. Additionally, such long-lasting augmenta-
tion of neuronal activity could have effects on receptor sensitivity
and trafficking or on synaptic plasticity. Indeed, this hM3Dq
mouse provides an attractive system for the study of synaptic
changes stemming from long-term activation of hippocampal
neuronal networks.
A final note of consideration regarding first- and second-gener-
ation RASSL, optoXR, and AlstR approaches is that the mecha-
nisms of neuronal modulation are indirect and dependent on
intracellular effectors. Here, in hM3Dq mice, neuronal activation
is secondary to coupling to PLCb, and the molecular mechanism
bywhich PLCb increases neuronal activity is incompletely under-
stood at this time. In contrast to systems that couple directly to an
ion channel with no intermediaries (e.g., channelrhodopsin and
TRPV1), it remains possible that if a given population of neurons
lacks the required molecular mediators downstream of PLCb,
these neurons may not respond to CNO, or may do so by
a different mechanism than that which we have hypothesized is
occurring here.
To conclude, in this study we describe the validation and utility
of the chemical-genetic DREADD approach, wherein a peripher-
ally administered, pharmacologically inert drug-like small mole-
cule (CNO) selectively modulates neuronal activity through an
evolved Gq-coupled GPCR. We have previously described the
in vitro use of a silencing Gi-coupled DREADD (hM4Di; Armbrus-
ter et al., 2007; Nawaratne et al., 2008), and a Gs-coupled
DREADD has also recently been developed (Conklin et al.,
2008; J.-M. Guettier et al., personal communication). Collec-
tively, these reagents provide useful tools for activating and
silencing neurons and for modulating distinct GPCR-coupled
signaling pathways in vivo.
EXPERIMENTAL PROCEDURES
Behavioral and biochemical experiments were performed at the University of
North Carolina and Case Western Reserve University, and all electrophysi-
ology experiments were performed at Duke University in accordance with
the National Institutes of Health’s guidelines for the care and use of animals
and with approved animal protocols from the Institutional Animal Care and
Use Committees of the aforementioned institutions. Detailed protocols for all
methods are described in Supplemental Experimental Procedures.
Generation of TRE-hM3Dq Mice
Inbrief,anHAepitope tagand thehM3Dqsequencewerecloned into theplasmid
pTre-Tight. The plasmid was then digested to generate TRE-HA-hM3Dq DNA,
andpronuclear injectionofB6SJLhybridmouseoocytesusing the2.36kbdiges-
tion productwas performed by theCase Transgenic and Targeting Facility (Case38 Neuron 63, 27–39, July 16, 2009 ª2009 Elsevier Inc.WesternReserveUniversity;Cleveland,OH).GenotypingwasperformedbyPCR
of genomic DNA extracted from tail clips. Upon identification, founder TRE-HA-
hM3DqmicewerecrossedwithCaMKIIa-tTAmice (TheJacksonLaboratory;Bar
Harbor, ME; Mayford et al., 1996). Gene expression in double-transgenic
(hM3Dq)micewasmaintained by raisingmice onadoxycycline-freediet. Protein
expression inmouse whole-brain homogenate was detected by immunoprecip-
itationwith anti-HA-affinity matrix followed bywestern detection. All immunohis-
tochemistry and radioligand binding procedures used to characterize receptor
expression are provided in Supplemental Experimental Procedures.
In Vitro Electrophysiology
Acute hippocampal slices were isolated from hM3Dq mice and littermate
controls (P18–P32), and whole-cell recordings weremade fromCA1 pyramidal
cells. CNO (500 nM to 1 mM) was bath applied, and changes in membrane
potential and spike activity were monitored.
Stereotypy and Locomotion
Activity was assessed by sessions in an open field chamber crossed by a grid
of photobeams (VersaMax system, AccuScan Instruments). An acclimation
interval preceded each trial, following which mice were injected with either
vehicle (saline) or CNO (Biomol International) in vehicle, i.p. and the trial initi-
ated. Counts were taken of the number of photobeams broken during the trial
in 5 min intervals, with separate measures for ambulation (total distance trav-
eled) and fine movements (repetitive beam breaks). Data from the first 15 min
following CNO administration were excluded from analyses in which data from
multiple 5 min intervals were pooled.
Seizure Activity
Behavioral seizure classification was based on a modified description of
Racine (Borges et al., 2003; Racine, 1972) with increasing seizure class repre-
senting increasing seizure severity.
In Vivo Electrophysiology
Multielectrode arrays were implanted bilaterally into the hippocampi of hM3Dq
and littermate control mice. Following a 1 week recovery period, animals were
administered either saline or varying doses of CNO (0.03–5mg/kg) while moni-
toring hippocampal LFP and single-unit firing of presumed hippocampal inter-
neurons.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, one
table, two movies, and eight figures and can be found with this article online
at http://www.cell.com/neuron/supplemental/S0896-6273(09)00467-X.
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